Jack W. Callicutt Sells 40,000 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Jack W. Callicutt sold 40,000 shares of the firm’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.89, for a total value of $35,600.00. Following the completion of the sale, the chief financial officer now directly owns 7,614 shares in the company, valued at approximately $6,776.46. This represents a 84.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Galectin Therapeutics Stock Up 32.2 %

Shares of GALT opened at $1.15 on Friday. The firm has a market capitalization of $72.18 million, a price-to-earnings ratio of -1.58 and a beta of 0.69. Galectin Therapeutics Inc. has a 12-month low of $0.73 and a 12-month high of $4.27. The stock’s 50-day moving average price is $2.34 and its 200 day moving average price is $2.43.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of GALT. JPMorgan Chase & Co. raised its stake in shares of Galectin Therapeutics by 161.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,628 shares of the company’s stock valued at $84,000 after buying an additional 18,907 shares in the last quarter. Barclays PLC raised its position in Galectin Therapeutics by 309.0% in the third quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after purchasing an additional 21,598 shares in the last quarter. Soltis Investment Advisors LLC bought a new position in Galectin Therapeutics during the third quarter worth about $387,000. Geode Capital Management LLC boosted its holdings in Galectin Therapeutics by 2.5% during the third quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock valued at $2,372,000 after purchasing an additional 20,817 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC bought a new stake in shares of Galectin Therapeutics in the 3rd quarter valued at approximately $117,000. 11.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on GALT shares. HC Wainwright reaffirmed a “neutral” rating on shares of Galectin Therapeutics in a report on Friday. StockNews.com raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th.

About Galectin Therapeutics

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.